The Potential of Pregabalin in Neurology, Psychiatry and Addiction: A Qualitative Overview
The DOI matches its Crossref record; 8 of the 8 references it cites were found in a registry or an index.
Abstract
Pregabalin is an anticonvulsant drug that binds to the α₂δ (alpha2delta) subunit of the voltage-dependent calcium channel in central nervous system (CNS). Pregabalin decreases the release of neurotransmitters, including glutamate, norepinephrine, substance P and calcitonin gene-related peptide. Purpose of this paper is to offer a qualitative overview of the studies currently available in literature about this drug, examining the effectiveness of pregabalin in its various fields of application. Our analysis, conducted on a final selection of 349 scientific papers, shows that pregabalin may help to reduce pain in diabetic neuropathy, in post-herpetic neuralgia and in some patients affected by fibromyalgia. It is also effective for the treatment of diverse types of seizures and has similar efficacy to benzodiazepines and venlafaxine in anxiety disorder. Moreover, pregabalin may be a therapeutic agent for the treatment of alcohol abuse, in both withdrawal phase and relapse prevention. Possible implications in the treatment of benzodiazepines dependence are emerging, but a potential abuse or misuse of the drug has also been reported. Range of dosage may fluctuate considerably, from 75 mg to 600 mg per day. Further studies are needed to completely understand pregabalin mechanism of action in the different diseases.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Early Identification of Refractory Epilepsy
Kwan, P., & Brodie, M. J. (2000) · New England Journal of Medicine · doi:10.1056/nejm200002033420503 · Cited by 5,204
Saitz, R. (2005) · New England Journal of Medicine · doi:10.1056/nejmcp042262 · Cited by 599 · cited 1×
“Until now, BDZ have been the first choice for AWS treatment [62, 63], thanks to their efficacy in ameliorating symptoms and decreasing seizure and delirium tremens risk [64].”
BackgroundManagement of Drug and Alcohol Withdrawal
Kosten, T. R., & O'Connor, P. G. (2003) · New England Journal of Medicine · doi:10.1056/nejmra020617 · Cited by 563
Mayo-Smith, M. F. (1997) · JAMA · doi:10.1001/jama.278.2.144 · Cited by 434
Drug therapy for alcohol dependence
Swift, R. M. (1999) · New England Journal of Medicine · doi:10.1056/nejm199905133401907 · Cited by 255 · cited 2×
“Is it possible to identify different forms, ranging from the mildest in which increased blood pressure and pulse rate, tremors, hyperreflexia, irritability, anxiety and depression are the most frequent signs [52,53], to the most severe forms characterized by delirium tremens [55], seizures [56] and coma [57], in which…”
BackgroundCrofford, L. J., Mease, P. J., Simpson, S. L., Young, J. P., Martin, S. A., Haig, G. M., & Sharma, U. (2008) · Pain · doi:10.1016/j.pain.2008.02.027 · Cited by 236
Pande, A. C., Feltner, D. E., Jefferson, J. W., Davidson, J. R. T., Pollack, M., Stein, M. B., Lydiard, R. B., Futterer, R., Robinson, P., Slomkowski, M., et al. (2004) · Journal of Clinical Psychopharmacology · doi:10.1097/01.jcp.0000117423.05703.e7 · Cited by 227
Carrus, D., & Schifano, F. (2012) · Journal of Clinical Psychopharmacology · doi:10.1097/jcp.0b013e318272864d · Cited by 49
Cited by
Chiappini, S., & Schifano, F. (2016) · CNS Drugs · doi:10.1007/s40263-016-0359-y · Cited by 189
Abrahamsson, T., Berge, J., Öjehagen, A., & Håkansson, A. (2017) · Drug and Alcohol Dependence · doi:10.1016/j.drugalcdep.2017.01.013 · Cited by 169
Barengolts, E., Green, S. J., Eisenberg, Y., Akbar, A., Reddivari, B., Layden, B. T., Dugas, L., & Chlipala, G. (2018) · PLoS ONE · doi:10.1371/journal.pone.0194171 · Cited by 111
Metadata
- Authors
- Martinotti, G., Lupi, M., Sarchione, F., Santacroce, R., Salone, A., Berardis, D., Serroni, N., Cavuto, M., Signorelli, M., Aguglia, E., Valchera, A., Iasevoli, F., & Giannantonio, M.
- Venue
- Current Pharmaceutical Design
- Publisher
- Bentham Science Publishers Ltd.
- Published
- 2013-09-01
- Volume
- 19
- Issue
- 35
- Pages
- 6367-6374
- ISSN
- 1381-6128 (ISSN-L)
- OpenAlex
- W1992366653
- Cited by
- 72
- References
- 8
- FWCI
- 4.90
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: The Potential of Pregabalin in Neurology, Psychiatry and Addiction: A Qualitative Overview. https://app.cochat.ai/papers/10.2174/13816128113199990425
- The paper
- Martinotti, G., Lupi, M., Sarchione, F., Santacroce, R., Salone, A., Berardis, D., Serroni, N., Cavuto, M., Signorelli, M., Aguglia, E., Valchera, A., Iasevoli, F., & Giannantonio, M. (2013). The Potential of Pregabalin in Neurology, Psychiatry and Addiction: A Qualitative Overview. Current Pharmaceutical Design. https://doi.org/10.2174/13816128113199990425
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.